University of Copenhagen-ko ikertzaileekin lankidetzan egindako argitalpenak (26)

2023

  1. Hepatitis delta infection among persons living with HIV in Europe

    Liver International, Vol. 43, Núm. 4, pp. 819-828

2022

  1. Observational cohort study of rilpivirine (RPV) utilization in Europe

    AIDS Research and Therapy, Vol. 19, Núm. 1

2021

  1. Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality—a multicentre prospective cohort study

    BMC Infectious Diseases, Vol. 21, Núm. 1

  2. Healthcare delivery for HIV-positive people with tuberculosis in Europe

    HIV Medicine, Vol. 22, Núm. 4, pp. 283-293

  3. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

    Journal of Acquired Immune Deficiency Syndromes, Vol. 87, Núm. 2, pp. 806-817

  4. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period

    AIDS (London, England), Vol. 35, Núm. 12, pp. 2025-2033

  5. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

    Annals of Internal Medicine, Vol. 174, Núm. 6, pp. 768-776

2019

  1. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

    AIDS, Vol. 33, Núm. 13, pp. 2013-2024

2018

  1. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

    HIV Medicine, Vol. 19, Núm. 4, pp. 252-260

  2. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

    HIV Medicine, Vol. 19, Núm. 2, pp. 102-117

  3. Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe

    HIV Medicine, Vol. 19, Núm. 5, pp. 324-338

  4. The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people

    HIV Medicine, Vol. 19, Núm. 2, pp. 90-101

2017

  1. HIV-1 infection in persons homozygous for CCR5-Δ32 allele: The next case and the review

    AIDS Reviews, Vol. 19, Núm. 4, pp. 219-230

2016

  1. Infection-related and -unrelated malignancies, HIV and the aging population

    HIV Medicine, Vol. 17, Núm. 8, pp. 590-600

  2. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study

    Medicine (United States), Vol. 95, Núm. 40

2015

  1. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

    HIV Medicine, Vol. 16, Núm. 9, pp. 533-543

  2. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration

    Journal of Acquired Immune Deficiency Syndromes, Vol. 69, Núm. 3, pp. 348-354

  3. Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals

    AIDS, Vol. 29, Núm. 10, pp. 1205-1215

2014

  1. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

    Infection, Vol. 42, Núm. 4, pp. 757-762

  2. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study

    BMC Nephrology, Vol. 15, Núm. 1